Drug Database
DO

donepezil (E 2022 / TK023 / TK 023)

✓ Approved

Eisai Co., Ltd. · ACHE · Small Molecule

What is donepezil?

donepezil is a small molecule developed by Eisai Co., Ltd.. It is approved for therapeutic indications via transdermal.

Drug Profile

Brand NamesE 2022, TK023, TK 023
CompanyEisai Co., Ltd.
Drug ClassSmall Molecule
Molecular TargetACHE
RouteTransdermal
StatusApproved
Sources: ClinicalTrials.gov, Eisai Co., Ltd.

Mechanism of Action

Molecular Targets

donepezil acts on 1 molecular target:

ACHEacetylcholinesterase (Cartwright blood group) (N-ACHE, ACEE)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

donepezil is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Nervous system disordersDementia Alzheimer's typePhase I

Related Research Articles

PubMedArthroscopy techniques2026-07-25

Trans-Tendon Suture-Bridge Knotless Proximal Pulley Repair With Bioinductive Patch Augmentation for High-Grade Partial Hip Abductor Tendon Tears.

Olarán Maria Agustina MA, Thamrongskulsiri Napatpong N, Casanova Felipe F, Vega Tomás F TF et al.

This technical note describes a knotless trans-tendon proximal-pulley repair with distal suture-bridge fixation and bioinductive collagen patch augmentation for high-grade partial gluteus medius and minimus tears. The technique preserves intact tendon fibers, restores broad footprint compression, and supports biologic healing through a resorbable collagen scaffold. Detailed steps emphasize anatomic anchor placement, controlled tensioning, and efficient suture management to improve construct reliability. This combined mechanical and biologic augmentation offers a promising option for enhancing tendon healing and optimizing outcomes in patients with degenerative high-grade partial-thickness abductor tears.

PMID 42499911
Read full article →
PubMedCureus2026-07-25

Use of a Serum With the Infinite Glow® Device Improves Signs of Facial Aging: A Split-Face Case Report Using VISIA Analysis.

Rodríguez Dominique D, Rodríguez Manuel M, Andersen Christopher C

An increase in wrinkles, laxity, and dyschromia characterizes facial-skin aging. The skin is a natural barrier that prevents or limits the entry of external therapeutic compounds to the body. Enhancing the efficacy of transdermal delivery of anti-aging compounds is a key therapeutic strategy. The study aimed to evaluate the efficacy and safety of a combined therapy that included a topical anti-aging serum and a multi-technology facial device designed to improve transdermal absorption. A 41-year-old woman with moderate facial aging was treated using a split-face design for 12 weeks. Every day, the left hemiface received a hyaluronic acid-niacinamide-Matrixyl serum. In contrast, the right hemiface received the same serum plus application of a multi-therapy device that delivered red light (630 nm), galvanic current, micro-vibration, and controlled heat. Skin changes were assessed using the VISIA Skin Analysis System (Canfield Scientific, Parsippany, New Jersey) at baseline, 6, and 12 weeks. Both hemifaces showed improvement in skin quality parameters (wrinkles, texture, and UV spots). TruSkin age decreased by five years on the treated side with the device + serum and by one year on the serum-only side. Greater improvement in wrinkle reduction was observed on the device-treated side. No adverse events were reported. As a preliminary observation, combined therapy using a topical serum and a multimodal device appears safe and attenuates aging effects, particularly in reducing wrinkles. Further studies are needed to confirm these findings.

PMID 42500768
Read full article →
PubMedMethodist DeBakey cardiovascular journal2026-07-25

Surgical Reconstruction of a Suprahepatic Inferior Vena Cava Aneurysm Using a Tubularized Bovine Pericardial Patch.

Achanta Laasya L, Benfor Bright B, Brooks Dylan E DE, Reardon Michael J MJ et al.

Inferior vena cava (IVC) aneurysms are rare clinical entities with fewer than 80 cases reported in the literature. Type I aneurysms involving the suprahepatic IVC present significant surgical challenges due to their proximity to the right atrium and the frequent necessity of cardiopulmonary bypass. We present the case of a 68-year-old female with a symptomatic, enlarging 6-cm type I IVC aneurysm. The patient underwent successful surgical resection and reconstruction using an interposition graft fashioned from a tubularized bovine pericardial patch under cardiopulmonary bypass. The postoperative course was unremarkable, and 6-month surveillance imaging confirmed graft patency without recurrence. This report highlights the feasibility of surgical intervention for symptomatic type I IVC aneurysms and describes a reconstructive technique using biologic material.

PMID 42499813
Read full article →
PubMedBioactive materials2026-07-25

Emerging bioactive microneedle platforms for disease management: From cutaneous disorders to systemic therapeutics.

Xiang Yiming Y, Gong Ziya Z, Liu Juying J, Zhu Yizhou Y et al.

Beyond their conventional role as passive transdermal delivery vehicles, microneedle (MN) platforms now function as active bio-interfaces capable of modulating therapeutic responses in both localized and systemic diseases. This review summarizes recent advances in MN technology, focusing on the transition from traditional matrix-controlled delivery to bioactive microneedles. Although localized applications at barrier surfaces, such as treating cutaneous disorders and mucosal lesions, remain a fundamental focus, this review emphasizes the application of MNs in complex chronic metabolic diseases (e.g., diabetes), oncology (e.g., melanoma and glioblastoma), and deep-tissue degenerative diseases of the cardiovascular, nervous, and musculoskeletal systems. Integrating stimuli-responsive materials, including metal-organic frameworks (MOFs), aggregation-induced emission luminogens (AIEgens), and smart hydrogels, with external physical stimuli enables autonomous, closed-loop interventions, thereby advancing personalized systemic therapy. Furthermore, we summarize recent progress in applying MNs to non-traditional sites and deep-tissue repair. Finally, rather than focusing solely on phenotypic efficacy, we discuss key translational challenges, including manufacturing scalability, biosafety, and regulatory pathways, to guide future clinical translation.

PMID 42499529
Read full article →
PubMedArthroscopy techniques2026-07-25

Reinforcing Anterosuperior Medium-to-Large Rotator Cuff Repairs With the Long Head of the Biceps Tendon and Dermal Allograft Patch Using a Knotless Double-Row Technique.

Escueta Gabriel Antonio A GAA, Chiu Joe Chih-Hao JC, Hung Al Kung-Tseng AK, C U Jijulal J et al.

We describe a surgical technique repairing medium-to-large anterosuperior rotator cuff (RC) tear that combines long head of the biceps tendon (LHBT) augmentation with a dermal allograft patch using a knotless double-row repair. LHBT augmentation is done using a triple-loaded anchor placed 5 mm posterior to the bicipital groove at the bone-cartilage junction. One suture strand creates a lasso-loop, rip-stop configuration to secure and posteriorly reroute the LHBT, improving anterior cable coverage. The remaining medial anchor sutures function as mattress sutures through the supraspinatus. Knots are tied, but the suture limbs are left uncut to secure the graft later to the cuff. A 3 × 3 cm, 2 × 2 mm thick dermal allograft is prepared. The uncut medial row sutures and a nonabsorbable tape suture (for lateral fixation) are passed through the graft. Using a custom cannula and traction sutures placed on the corners, the graft is shuttled and positioned on the bursal side of the repaired tendon. Once positioned, the medial sutures are secured. All remaining sutures (medial limbs, nonabsorbable tape suture, and traction sutures) are loaded into a lateral row anchor and impacted into the greater tuberosity. The final construct sandwiches the repaired tendon beneath the allograft, increasing construct thickness and ensuring complete footprint coverage.

PMID 42499914
Read full article →
PubMedNeural networks : the official journal of the International Neural Network Society2026-07-25

Multi-granularity cross-image semantic modeling for medical ultrasound image segmentation.

Lu Xiaoyan X, Yuan Wenhao W, Gong Xun X, Ma Chong C

Automatic segmentation of medical ultrasound images is critical for computer-aided diagnosis (CAD). However, most existing methods primarily exploit within-image semantics while neglecting cross-image semantic modeling. By leveraging cohort-level shape and echotexture priors, cross-image semantic modeling improves robustness against inter-patient and inter-scanner variations. Nevertheless, positional correlations in cross-image scenarios may incorrectly map foreground features from previous images onto background regions of the current one, causing semantic conflicts that degrade segmentation reliability. Moreover, many methods emphasize global context while overlooking fine-grained lesion information. To address these limitations, we propose Multi-granularity Cross-image Semantic Modeling (MCSM), where multi-granularity denotes the joint modeling of global (whole-image) and local (lesion-centric local patch) representations. Specifically, we first design a Multi-Granularity Patch Extraction Process (MGPEP) that extracts lesion patches and fuses them with whole-image features to strengthen cross-image semantics. We then propose a Frequency-domain Feature Dependency Module (FFDM) that performs multi-granularity spectral filtering to capture cross-image dependencies. During training, features from preceding batches (i.e., previous images) are mapped to the frequency domain to extract latent semantic correlations and are integrated into current batches (i.e., current image) representation, thereby enhancing foreground-background discrimination. In addition, we employ dual-mean filtering to suppress high-frequency noise in the global spectrum. Extensive experiments demonstrate the effectiveness and robustness of MCSM over state-of-the-art methods, highlighting its potential for clinical application. Code and models are available at https://github.com/XyL215/MCSM.

PMID 42497540
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about donepezil